Literature DB >> 571572

Cellular immune response to acetylcholine receptor in myasthenia gravis: II. Thymectomy and corticosteroids.

M Morgutti, B M Conti-Tronconi, A Sghirlanzoni, F Clementi.   

Abstract

We studied 11 patients with myasthenia gravis who demonstrated a cellular immune response to acetylcholine receptor (AChR) of the electric organ of Torpedo marmorata. After thymectomy, there was a marked decrease in the patients' lymphocyte reactivity to AChR. The mean reduction of the stimulation index (SI) was 50%, but the response to the nonspecific mitogen phytohemagglutinin (PHA) was not affected. In six cases, the lymphocyte response was measured at intervals up to 22 months after thymectomy; in all six, the immune response to AChR remained decreased. In some cases, the response continued to decrease, even to normal values. The effect of corticosteroid treatment was tested in other patients. The cellular immune response to AChR was significantly lower in treated patients (mean SI, 1.64 +/- 0.25) than in untreated controls (mean SI, 2.41 +/- 0.38), with no significant difference in the response to PHA. These data suggest that a decrease in the cellular immune response to AChR may be one mechanism by which thymectomy and corticosteroids are therapeutic in myasthenia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 571572     DOI: 10.1212/wnl.29.5.734

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Specific involvement of peripheral T lymphocytes against acetylcholine receptors in myasthenia gravis.

Authors:  B M Conti-Tronconi; A Scotti; A Sghirlanzoni; F Clementi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-09       Impact factor: 10.154

Review 2.  Immunopathology of acetylcholine receptors in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Springer Semin Immunopathol       Date:  1982

3.  Lymphocyte populations in patients with myasthenia gravis. Influence of thymectomy and immunosuppressive drugs.

Authors:  G Ippoliti; G Piccolo; M Lombardi; G Carnevale Maffé; V Cosi; P Pinelli
Journal:  Ital J Neurol Sci       Date:  1982-12

4.  Identification of T-cell epitopes of autoantigens using recombinant proteins; studies on experimental autoimmune myasthenia gravis.

Authors:  Y Zhang; S Frutiger; G J Hughes; M C Savoy; T Barkas
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

Review 5.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

6.  Localized thymic amyloidosis presenting with myasthenia gravis: case report.

Authors:  Seung-Myoung Son; Yong-Moon Lee; Si Wook Kim; Ok-Jun Lee
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

7.  Cellular and humoral immunity to acetylcholine receptor in myasthenia gravis.

Authors:  B M Conti Tronconi; A Scotti; A Brigonzi; E Sher; G Fumagalli; D Peluchetti; F Clementi
Journal:  Ital J Neurol Sci       Date:  1982-03

8.  Myasthenia gravis, thymectomy, and antiacetycholine receptor antibody.

Authors:  E Bartoccioni; F Scuderi; C Scoppetta; A Evoli; P Tonali; L Guidi; C Bartoloni; T Terranova
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

9.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

10.  Myasthenia gravis: a review.

Authors:  Annapurni Jayam Trouth; Alok Dabi; Noha Solieman; Mohankumar Kurukumbi; Janaki Kalyanam
Journal:  Autoimmune Dis       Date:  2012-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.